Novo Nordisk A/S (NYSE:NVO) Shares Gap Up – Here’s What Happened

Novo Nordisk A/S (NYSE:NVO)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $57.12, but opened at $59.91. Novo Nordisk A/S shares last traded at $59.8510, with a volume of 9,248,604 shares trading hands.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Early U.S. launch momentum — IQVIA data show 3,071 prescriptions for oral Wegovy in the first four days, suggesting solid initial demand and supporting first-mover advantage versus Eli Lilly. Novo’s Wegovy pill tracks 3,071 prescriptions in first days of launch
• Positive Sentiment: Positive market reaction to early prescription figures — coverage from CNBC/analysts called the start “solid,” helping lift sentiment as investors await further cadence data. Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch
• Positive Sentiment: Regulatory uplift in the U.K. — U.K. approval of a higher semaglutide (Wegovy) dose to 7.2 mg expands label and addressable patient population for the injectable franchise. Novo Nordisk’s Wegovy Weight Loss Shot Approved At Higher Dose in U.K.
• Neutral Sentiment: Analyst caution on early reads — UBS warns early prescription snapshots may not reflect full demand and raised its PT despite flagging limitations of initial data. Novo Nordisk obesity pill unlikely to impress early, UBS warns
• Neutral Sentiment: Management view on pricing pressure — CEO commentary signals 2026 will see increased price pressure as supply and deals expand; important longer-term margin watch. Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
• Negative Sentiment: Legal/antitrust risk — a compounding pharmacy has sued Novo (and Eli Lilly) over GLP‑1 access, and media coverage of the suit has already pressured the stock in recent sessions. Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access
• Negative Sentiment: Market/legal headlines depressed sentiment this week — coverage of an antitrust-style suit and valuation skepticism weighed on the stock prior to the positive launch data. Novo Nordisk Stock Dips As Company Faces GLP-1 Antitrust Lawsuit

Analyst Ratings Changes

A number of equities analysts recently issued reports on NVO shares. Jefferies Financial Group started coverage on Novo Nordisk A/S in a research report on Monday, October 27th. They issued an “underperform” rating on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday, December 29th. The Goldman Sachs Group dropped their target price on Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating on the stock in a report on Friday, November 28th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a report on Wednesday. Finally, HSBC reiterated a “hold” rating and issued a $54.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $56.21.

Novo Nordisk A/S Stock Up 8.0%

The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. The company has a market capitalization of $275.35 billion, a PE ratio of 17.91 and a beta of 0.66. The firm’s 50-day simple moving average is $50.51 and its 200 day simple moving average is $55.12.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The business had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Institutional Investors Weigh In On Novo Nordisk A/S

Several institutional investors have recently modified their holdings of the company. Franklin Resources Inc. raised its holdings in Novo Nordisk A/S by 4,190.8% during the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after purchasing an additional 13,658,867 shares during the last quarter. Kingstone Capital Partners Texas LLC grew its holdings in Novo Nordisk A/S by 301,443.6% in the second quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock valued at $690,560,000 after purchasing an additional 10,001,898 shares during the last quarter. Capital International Investors increased its position in shares of Novo Nordisk A/S by 52.4% in the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after buying an additional 6,092,192 shares in the last quarter. Boston Partners acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter worth $310,199,000. Finally, SG Americas Securities LLC raised its stake in shares of Novo Nordisk A/S by 2,101.5% during the 3rd quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock worth $132,242,000 after buying an additional 2,274,925 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.